Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Kristen B. Bresnehan PharmD

Kristen B. Bresnehan PharmD profile photo picture

Assistant Professor

Institution: Medical College of Wisconsin
Department: School of Pharmacy Administration
Division: Administration
Program: Administration

Member of the Neuroscience Research Center

Research Experience

  • Gram-Negative Bacterial Infections
  • Gram-Positive Bacterial Infections
  • Pharmacokinetics
  • Pneumonia, Ventilator-Associated
  • Renal Replacement Therapy
  • Clinical Expertise

  • Antimicrobial Stewardship
  • Critical Care
  • Infectious Disease Medicine
  • Travel Medicine
  • Publications (16)

  • Aminopenicillins for treatment of ampicillin-resistant enterococcal urinary tract infections. (Bunnell K, Duong A, Ringsred T, Mian A, Bhathena S) Am J Health Syst Pharm 2022 06 23;79(13):1056-1065 PMID: 35299243 SCOPUS ID: 2-s2.0-85133100597 03/18/2022    
  • Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects. (Wenzler E, Meyer KM, Bleasdale SC, Sikka M, Mendes RE, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA) Antimicrob Agents Chemother 2020 01 27;64(2) PMID: 31767717 PMCID: PMC6985713 SCOPUS ID: 2-s2.0-85078572928 11/27/2019       2 Citations
  • Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With Enterobacteriaceae Bloodstream Infections. (SantibaƱez M, Bunnell K, Harrington A, Bleasdale S, Wenzler E) Open Forum Infect Dis 2019 Oct;6(10):ofz400 PMID: 31660362 PMCID: PMC6790397 SCOPUS ID: 2-s2.0-85084500006 10/30/2019    
  • Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. (Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA, Antibacterial Resistance Leadership Group) Antimicrob Agents Chemother 2018 08;62(8) PMID: 29891606 PMCID: PMC6105781 SCOPUS ID: 2-s2.0-85052025758 06/13/2018       16 Citations
  • Effectiveness of Probiotic for Primary Prevention of Clostridium difficile Infection: A Single-Center Before-and-After Quality Improvement Intervention at a Tertiary-Care Medical Center. (Trick WE, Sokalski SJ, Johnson S, Bunnell KL, Levato J, Ray MJ, Weinstein RA) Infect Control Hosp Epidemiol 2018 07;39(7):765-770 PMID: 29695310 SCOPUS ID: 2-s2.0-85046035670 04/27/2018       8 Citations
  • Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae. (Bunnell KL, Wenzler E, Harrington AT, Danziger LH) Diagn Microbiol Infect Dis 2018 Apr;90(4):335-336 PMID: 29395714 SCOPUS ID: 2-s2.0-85040785405 02/06/2018       4 Citations
  • Immunologic and Virologic Outcomes of Obese and Nonobese Incarcerated Adults on Antiretroviral Therapy for HIV Infection. (Bunnell KL, Aldossari A, Perkins C, Schriever C, Chiampas TD, Young JD, Patel MC, Badowski M) J Int Assoc Provid AIDS Care 2018 Jan-Dec;17:2325957417752261 PMID: 29357770 PMCID: PMC6748539 SCOPUS ID: 2-s2.0-85059112546 01/24/2018    
  • Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects. (Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA) Antimicrob Agents Chemother 2018 04;62(4) PMID: 29311094 PMCID: PMC5913990 SCOPUS ID: 2-s2.0-85044519836 01/10/2018       6 Citations
  • Clinical use of the polymyxins: the tale of the fox and the cat. (Wenzler E, Bunnell KL, Danziger LH) Int J Antimicrob Agents 2018 May;51(5):700-706 PMID: 29305954 SCOPUS ID: 2-s2.0-85044530489 01/07/2018       12 Citations
  • Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile. (Guinta MM, Bunnell K, Harrington A, Bleasdale S, Danziger L, Wenzler E) Ann Clin Microbiol Antimicrob 2017 Dec 04;16(1):77 PMID: 29202797 PMCID: PMC5713042 SCOPUS ID: 2-s2.0-85037343720 12/06/2017       4 Citations
  • Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin. (Bunnell KL, Danziger LH, Johnson S) Open Forum Infect Dis 2017;4(2):ofx078 PMID: 28638841 PMCID: PMC5472230 SCOPUS ID: 2-s2.0-85031917537 06/24/2017       15 Citations
  • Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration. (Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA) Antimicrob Agents Chemother 2017 07;61(7) PMID: 28416553 PMCID: PMC5487628 SCOPUS ID: 2-s2.0-85022091860 04/19/2017       25 Citations
  • Methicillin-Resistant Staphylococcus aureus Pneumonia in Critically Ill Trauma and Burn Patients: A Retrospective Cohort Study. (Bunnell KL, Zullo AR, Collins C, Adams CA Jr) Surg Infect (Larchmt) 2017 Feb/Mar;18(2):196-201 PMID: 28004983 SCOPUS ID: 2-s2.0-85013287760 12/23/2016       4 Citations
  • Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. (Bunnell KL, Vibhakar S, Glowacki RC, Gallagher MA, Osei AM, Huhn G) Pharmacotherapy 2016 09;36(9):e148-53 PMID: 27459733 SCOPUS ID: 2-s2.0-84990227022 07/28/2016       24 Citations
  • Levetiracetam-induced neutropenia following traumatic brain injury. (Bunnell K, Pucci F) Brain Inj 2015;29(1):115-7 PMID: 25153852 SCOPUS ID: 2-s2.0-84917710482 08/26/2014       3 Citations
  • Exposure of cyclosporin A in whole blood, cerebral spinal fluid, and brain extracellular fluid dialysate in adults with traumatic brain injury. (Brophy GM, Mazzeo AT, Brar S, Alves OL, Bunnell K, Gilman C, Karnes T, Hayes RL, Bullock R) J Neurotrauma 2013 Sep 01;30(17):1484-9 PMID: 23540442 PMCID: PMC3751213 SCOPUS ID: 2-s2.0-84882724043 04/02/2013       14 Citations
  • Last update: 09/22/2022